Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia
Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia
The primary objective is to assess the dose-response relationship of SL77.0499 10 (alfuzosin
 hydrochloride) 5 mg, 10 mg, 15 mg, and placebo once daily during a 12-week oral
 administration period for the efficacy in patients with lower urinary tract symptoms (LUTS)
 related to BPH.

 Secondary objectives are to assess the efficacy of each dose of alfuzosin as compared with
 placebo and to assess the safety of each dose of alfuzosin.
Inclusion Criteria:

 -  suffering from LUTS related to BPH for at least 6 months;

 -  having an IPSS >13;

 -  having a urinary peak flow rate 5.0 to 12.0 mL/s for a voided volume of at least 150
 mL;

 -  having a residual urine volume < or = 200 mL.